Sorrento Therapeutics

relapsed-refractory-marginal-zone-lymphoma-reacts-abivertinib

Relapsed/Refractory Marginal Zone Lymphoma Reacts to Abivertinib

SG Tylor

A Phase IIa trial conducted in China demonstrated that treatment with the irreversible BTK inhibitor abivertinib (Fujovee) resulted in responses ...